RespirAct Gas Challenge for Heart Disease Detection
(NIMO-Healthy Trial)

Recruiting in Palo Alto (17 mi)

Age: 18+

Sex: Any

Travel: May Be Covered

Time Reimbursement: Varies

Trial Phase: Academic

Waitlist Available

Sponsor: Indiana University

No Placebo Group

Trial Summary

What is the purpose of this trial?This is a prospective pilot study to evaluate the safety, tolerability and efficacy of utilizing precise computer controlled gas challenge in healthy subjects for identification of coronary artery disease.

Eligibility Criteria

This clinical trial is open to adults aged 45 and older who have no known heart disease. Participants must be able to increase their breathing rate when asked, not be pregnant or nursing, don't have an IUD, can lie on their back for up to 40 minutes, and don't suffer from serious neurological, lung, kidney or liver diseases.

Inclusion Criteria

I do not have any heart diseases.

I am 45 years old or older.

Exclusion Criteria

My blood pressure is usually below 100/60.

You can't speed up your breathing when asked to do so.

I cannot lie on my back for 30-40 minutes.

+4 more

Participant Groups

The study is testing the safety and effectiveness of a needle-free method called RespirAct. It involves controlled breathing challenges using computer precision to detect coronary artery disease in healthy individuals.

4Treatment groups

Experimental Treatment

Group I: Hypoxia GroupExperimental Treatment1 Intervention

Healthy subjects without a history of coronary artery disease will undergo computer-controlled gas challenges.

Group II: Hypercapnia Group CExperimental Treatment1 Intervention

Healthy subjects without a history of coronary artery disease will undergo computer-controlled gas challenges.

Group III: Hypercapnia Group BExperimental Treatment1 Intervention

Healthy subjects without a history of coronary artery disease will undergo computer-controlled gas challenges.

Group IV: Hypercapnia Group AExperimental Treatment1 Intervention

Healthy subjects without a history of coronary artery disease will undergo computer-controlled gas challenges.